Cincinnati, OH – November 18, 2013 –Ethicon Endo-Surgery, Inc. (Ethicon) Energy business, market leaders in advanced energy surgical devices, today announced that it has entered into a collaboration agreement with MEGADYNE®, market leaders in electrosurgery. Per the terms of the agreement, Ethicon and MEGADYNE® will now offer contracting solutions for customers in the U.S. that will increase choice and access to a broad energy portfolio across multiple energy platforms, from monopolar and standard bipolar currently offered by MEGADYNE® to advanced bipolar and ultrasonic currently offered by Ethicon.
“This partnership provided our hospital system with a comprehensive portfolio of solutions for our energy needs” said Sonja L. Glass, RN, BSN, Value Analysis Coordinator for Surgical Services, Strategic Sourcing (Wake Forest Baptist Medical Center, Winston Salem, North Carolina). “I believe Ethicon and Megadyne provide high quality products that help us deliver quality outcomes for our patients. The partnership helped drive cost efficiencies and provided financial benefits for Wake Forest Baptist.”
This collaboration not only provides customers greater choice of energy solutions to simplify their inventory management, but we can now also offer increased value through flexible contracting solutions, capital trade-out programs, product and supplier standardization and environmentally friendly solutions.
“Our companies share a common vision to advance surgery and improve patient outcomes through high quality standards, intuitive to use products and a customer solutions mindset”, said Michelle Brennan, Worldwide President for the Ethicon Energy business. “Now leveraging our combined scope and scale, we can provide a comprehensive portfolio of solutions across the spectrum of energy platforms.”
For more information about the Ethicon/ MEGADYNE® partnership, physicians and hospitals can contact their local Ethicon Energy sales representative or call 1-800-USE-ENDO.
About Our Energy Business
Ethicon is a leader in advanced energy solutions and offers the broadest portfolio of ultrasonic energy devices using HARMONIC® technology and advanced bipolar energy devices using ENSEAL® technology. Click here to learn more.
HARMONIC® ultrasonic devices combine precision and multifunctionality: With a jaw and blade uniquely designed for precise dissection, sealing and transection, one device enables surgeons to perform multiple jobs without instrument exchanges. HARMONIC® technology is the proven leader in advanced energy with more than 16 million procedures worldwide[1]. Click here to learn more.
ENSEAL® advanced bipolar devices are strong on sealing, yet gentle on tissue. With an I-BLADE® that delivers high uniform compression along the entire length of the jaw, ENSEAL® seals vessels up to 7mm in diameter. The ENSEAL® G2 Tissue Sealer portfolio also includes the ENSEAL® G2 Super Jaw device, launched in 2011, and the ENSEAL® G2 Curved and Straight Tissue Sealers, launched in 2012 as well as the newly released ENSEAL® G2 Articulating Tissue Sealer. Click here to learn more.
About Our Company
Ethicon represents the products and services of Ethicon, Inc. and Ethicon Endo-Surgery, Inc., two companies with long histories of medical innovation, which provide globally a broad range of surgical technologies and products (including energy devices, sutures, staplers, clip appliers, trocars and meshes) used to treat colorectal and thoracic conditions, women’s health conditions, hernias, cancer and obesity. Ethicon, Inc. and Ethicon Endo-Surgery, Inc. are part of the Johnson & Johnson Family of Companies. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon.
Safe Harbor Statement
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ethicon and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Ethicon nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)
###
[1] Internal sales data as of June 10, 2013.
Contact:
Energy Worldwide Communications
Bridgett Golden
513-375-9524
bgolden@its.jnj.com
Ann Leibson
513-479-1210
aleibso@its.jnj.com